Statement of Principles concerning cirrhosis of the liver (Reasonable Hypothesis) (No. 1 of 2017)

The SOP revolves around several discrete legal‑medical concepts. First, cirrhosis of the liver is specifically defined for this instrument as “a chronic condition of the hepatic parenchyma involving severe fibrosis in association with the formation of regenerative nodules” (s 7(2)). The instrument notes ICD‑10‑AM codes that commonly attract to cirrhosis but instructs that the statutory meaning is the definition in s 7(2) (s 7(3)-(4)).

Second, “reasonable hypothesis” is the statutory standard which this SOP is designed to operationalise by listing what factors must exist to raise the reasonable hypothesis that cirrhosis (or death from it) is connected to relevant service. Section 9 is the central list. It includes exposure thresholds (quantifiable exposures such as alcohol, ionising radiation, vinyl chloride, carbon tetrachloride, vitamin A, methotrexate, and specified antiretroviral drugs), documented disease states (chronic infection with hepatitis B, C, D, and E; chronic hepatitis; autoimmune chronic active hepatitis; steatohepatitis; granulomatous liver disease), genetic/metabolic conditions (Wilson's disease, alpha-1 antitrypsin deficiency, Gaucher's disease, iron overload), and clinical syndromes impacting liver physiology (Budd‑Chiari syndrome, veno‑occlusive disease, severe right‑sided cardiac failure, obstructive biliary disease). The list is split between factors relevant to clinical onset and factors relevant to clinical worsening, with many factors repeated for both endpoints (see s 9 generally).

Third, timing and relation to service are key. The factors must have existed in the person and must be related to the person’s relevant service (s 10(1)). The SOP distinguishes between factors that can materially contribute to or aggravate cirrhosis where cirrhosis was suffered or contracted prior to or during relevant service (but did not arise out of service), namely the subset in subsections 9(28)-9(55) (s 10(2)). The instrument therefore embeds different causal pathways: factors that may be causal for onset, and factors that may be causal for worsening or aggravation.

Fourth, definitions in the Schedule shape evidentiary standards. For example, chronic infection with hepatitis B, C or D is defined as infection of at least six months duration confirmed by laboratory testing for serological or nucleic acid markers (Schedule 1). Alcohol consumption is measured by defining a standard drink as containing ten grams of alcohol (Schedule 1). “Cumulative equivalent dose” of ionising radiation is defined and refers decision makers to the ARPANSA dose‑reconstruction methodology current on 2 August 2017 (Schedule 1). The SOP therefore delegates technical measurement methods to an external technical guide.

Fifth, cross‑reference rules: if a factor in s 9 refers to an injury or disease for which another SOP exists, that other SOP governs the application of that factor per section 11. This creates a priority/consistency rule across SOPs so that where a factor overlaps with another SOP, the other instrument’s terms apply.

Finally, the instrument expressly includes death from cirrhosis within its scope. Death is covered where a terminal event or condition was contributed to by the person's cirrhosis (s 7(5)), and “terminal event” is defined in the Schedule to include causes such as pneumonia, respiratory failure, cardiac arrest and circulatory failure. These definitions matter for claims where cirrhosis is a contributing cause rather than the proximate cause.

These concepts together operationalise the RMA’s view (s 8) and set out the discrete evidence a claimant must marshal to satisfy the statutory “reasonable hypothesis” standard in the context of VEA and MRCA claim processing (s 5).

The SOP applies to persons pursuing claims that fall within the statutory claim pathways referenced in section 5. Specifically, section 5 states that the instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies. The Schedule defines “relevant service” to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1: relevant service, items (a)-(f)). Therefore affected persons include:

• veterans and former members of Defence who assert entitlement under the VEA for cirrhosis or death from cirrhosis in respect of relevant VEA service categories listed in the Schedule; and

• persons making claims under the MRCA in relation to comparable categories of service (warlike and non‑warlike service).

The SOP also affects decision makers within the Department of Veterans’ Affairs, members of the Repatriation Commission and tribunals that apply VEA/MRCA claims, as they will use the factors and definitions in this instrument when assessing whether a reasonable hypothesis has been raised (s 3, s 9, s 10, s 11). The RMA’s determination that there is sound medical‑scientific evidence linking cirrhosis and death from cirrhosis to relevant service (s 8) is the basis on which those agencies rely when applying the SOP to individual claims.

Health professionals preparing evidence for claimants are affected insofar as the SOP prescribes the kinds of clinical and laboratory findings and exposure histories that are material: for example, confirmation of chronic hepatitis B, C or D requires laboratory serological or nucleic acid markers for at least six months (Schedule 1). Employers and third parties are indirectly affected where their records contain evidence relevant to a threshold in the SOP, for example occupational exposure records (vinyl chloride hours or ppm‑years, carbon tetrachloride hours, radiation dose records) that may be needed to establish a factor in s 9.

Family members and estates are affected where death from cirrhosis is claimed, because the SOP includes death caused or contributed to by a terminal event linked to cirrhosis (s 7(5) and Schedule: terminal event). Finally, the SOP affects persons previously denied under the revoked SOP (s 4) by replacing the older determinative framework; in practical terms the revised thresholds and definitional clarifications will change which claims raise a reasonable hypothesis.

The instrument does not create criminal offences or civil liabilities. Its effect is limited to evidentiary and determinative application in the statutory claims processes specified in s 5. The SOP therefore affects rights to claim and the evidentiary burden required to raise a reasonable hypothesis in those administrative processes.

This instrument does not itself impose duties that create direct regulatory penalties; rather it prescribes the medical factors and definitions used by decision makers to determine whether a claimant has established a reasonable hypothesis connecting cirrhosis of the liver, or death from cirrhosis, to relevant service.

Rights:

• The instrument defines what constitutes cirrhosis for the purpose of claims: the statutory definition in s 7(2) is binding for claims within the instrument’s scope.

• Claimants have the right to have their claim assessed against the factors in s 9 and the definitional rules in Schedule 1. When a factor listed in s 9 is established and related to relevant service (s 10(1)), a reasonable hypothesis is raised in the terms the RMA has set.

• Where a factor in s 9 overlaps with a disease/injury covered under another SOP, the claimant’s rights to have that factor assessed are governed by the terms of that other SOP, per s 11. That cross‑reference constitutes a right to consistent application of other SOPs.

Duties and obligations on decision makers and evidence requirements (implicit in the text):

• Decision makers are required to apply the factors and definitions in this instrument when considering whether a reasonable hypothesis exists (ss 3, 8, 9, 10). The RMA’s view in s 8 provides the evidential foundation, and the Schedule prescribes specific laboratory and measurement requirements (for example, chronic infections defined by at least six months duration and laboratory confirmation; alcohol measured by 10 g per standard drink).

• For factors involving ionising radiation, decision makers will refer to the ARPANSA Guide to calculation of ‘cumulative equivalent dose’ as in force on 2 August 2017 (Schedule 1). That guide supplies the methodological duty for dose reconstruction when establishing s 9(3) or s 9(30) factors.

• For factors that are time‑bound or dose‑bound (for example alcohol, vitamin A, vinyl chloride, carbon tetrachloride, methotrexate, and named dideoxynucleoside-analogue drugs), the claimant must provide (or decision makers must obtain) evidence that matches the threshold wording in s 9. The Schedule’s definitions provide the standard of proof for chronic infections and other clinical entities.

• Section 10(2) imposes an interpretive constraint: subsections 9(28)-9(55) apply only to “material contribution to, or aggravation of” cirrhosis where the cirrhosis was suffered or contracted before or during (but did not arise out of) relevant service. That means decision makers must establish both the temporal relationship of disease onset relative to service and whether the service‑related exposure materially contributed or aggravated the condition.

Operational consequences (rights of record use and evidentiary reliance):

• The SOP permits, and in practice requires, reliance on non‑medical records where those records are necessary to demonstrate exposure thresholds: occupational exposure logs for vinyl chloride or radiation, prescriptions and dosing records for methotrexate and the named antiretroviral agents, transfusion or ferritin/transferrin tests showing iron overload, and clinical records confirming obstructive biliary disease or veno‑occlusive disease.

• The Schedule’s laboratory‑centred definitions create a right for the claimant to have laboratory evidence assessed, and a duty on decision makers to treat specified laboratory markers (serological or nucleic acid markers) as the confirmatory standard for chronic infections (Schedule 1: chronic infection definitions).

The instrument affords claimants a predictable legal framework for what constitutes sufficient medical and exposure evidence to raise a reasonable hypothesis, and it constrains decision makers to apply those thresholds and definitions when conducting entitlement assessments under the VEA and MRCA pathways referenced in section 5.

The SOP itself establishes no criminal sanctions, civil penalties, or direct enforcement mechanisms. It is a determinative evidentiary instrument used in administrative decision making under the VEA and MRCA. Enforcement in practical terms is effected by the decision makers who apply the SOP when determining claims under the statutory provisions cited in section 5. The instrument does not create new enforcement machinery; it supplies the medical standards used by existing processes.

What the instrument does enforce indirectly:

• Decision makers will use the SOP to decide whether a claimant has raised the statutory “reasonable hypothesis” test. Establishing the factors in s 9 and satisfying the relationship to relevant service in s 10 are the determinative evidentiary tests the administering agencies will apply. Where a claimant fails to establish the factors as set out, entitlement under the relevant claim provisions is unlikely to be found.

• The instrument’s definitional and measurement standards impose practical evidentiary burdens. For example, the definitions of chronic hepatitis and chronic infections in the Schedule require laboratory confirmation for a period of at least six months (Schedule 1). Failure to produce laboratory evidence consistent with those definitions will typically mean a claimant does not meet the SOP thresholds.

• The SOP makes clear that for ionising radiation dose assessment, the ARPANSA guide shall be used (Schedule 1). That means dose reconstruction methodology and assumptions in that guide will be applied; a claimant who lacks adequate radiation exposure records will be limited in raising the s 9(3) or s 9(30) radiation factors.

Appeals and review mechanisms are not described in the SOP text. The SOP functions within the broader VEA/MRCA administrative scheme, where review and appeal rights are governed by those Acts. The SOP itself does not alter appeal rights; it only supplies the medical criteria that will be relied upon during decision making.

Because the instrument contains no penalty provisions, enforcement risk for non‑compliance by claimants is effectively the risk of denial of entitlement. For practitioners advising claimants, the operational enforcement landscape is therefore administrative: the “penalty” for failing to meet the s 9 thresholds is non‑entitlement under the relevant statutory claim provisions.

Decision makers’ obligations to adhere to the SOP are implicit in the statutory scheme under which the RMA issues SOPs (subsection 196B(2) of the VEA), and agencies handling claims will typically be expected to apply SOPs when assessing reasonable hypothesis issues. The SOP therefore functions as binding guidance within that statutory administrative framework.

This SOP is made under subsection 196B(2) of the Veterans’ Entitlements Act 1986 (s 3). Section 5 expressly limits its application to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 (MRCA) applies. It therefore sits inside the VEA/MRCA claims architecture and operates only within those statutory claim pathways.

Cross‑instrument interaction rules:

• Section 11 provides a direct interaction rule between SOPs. If a factor in s 9 refers to an injury or disease that is the subject of another SOP, the factors in that other SOP apply in accordance with its terms. That creates an inter‑instrument precedence/consistency mechanism so that overlapping medical matters are decided using the SOP already in force for the other disease/injury. Practically, this avoids contradictory medical standards across SOPs by deferring to the more specifically applicable SOP.

• The Schedule’s definition of “cumulative equivalent dose” explicitly incorporates an external administrative instrument, namely the ARPANSA Guide to calculation of ‘cumulative equivalent dose’ as in force on 2 August 2017. This is an example of the SOP referencing a technical standard from another statutory/regulatory body (Australian Radiation Protection and Nuclear Safety Agency). The SOP thus interacts with ARPANSA’s methodological guidance for dose reconstruction, creating an external technical dependency in claims involving ionising radiation (Schedule 1: cumulative equivalent dose).

Relationship to VEA and MRCA:

• The SOP does not itself change the rights and obligations created by the VEA or MRCA. Rather, it provides a determinative medical framework used in adjudicating entitlements under those Acts. Where the VEA or MRCA contain procedural rules, appeal mechanisms, or definitions that are relevant to claims, those provisions govern the procedural handling of claims. The SOP supplies the medical thresholds decision makers must apply in that procedural context.

• The instrument revokes the earlier Statement of Principles concerning cirrhosis of the liver No. 107 of 2007 (s 4). This means existing claims previously assessed against the 2007 SOP will, for future assessments, be considered against the new SOP. Transitional or saving provisions, if any, that affect earlier decisions are not included in the text of the SOP; the compilation notes that application, saving and transitional provisions for amendments are included in the endnotes where relevant. Practitioners should check endnote materials for transition rules (endnotes).

Interaction with other statutory regimes and evidence law:

• The SOP’s laboratory and measurement standards (for chronic infections, radiation dose, and pharmacological thresholds) require reliance on medical testing and technical reports. The SOP does not itself mandate evidentiary rules (for example, admissibility), but in practice those evidentiary matters are dealt with under the VEA/MRCA administrative and tribunal rules. Where a factor refers to exposure in an occupational context (vinyl chloride, carbon tetrachloride) or to drug treatment records, relevant industrial safety legislation or medical privacy laws may affect the practical availability of records needed to establish a factor. Those interactions are outside the text of this SOP but are relevant when operationalising it in claims.

• The Schedule’s reference to ICD‑10‑AM codes (s 7(3)-(4)) ties diagnostic classification systems used in Australian clinical settings to the SOP, but it clarifies that the statutory definition in s 7(2) is determinative even where ICD codes differ.

In short, this SOP functions within the VEA/MRCA statutory framework, cross‑refers to other SOPs where relevant, and imports external technical guidance for radiation dose calculations (ARPANSA). It does not create new statutory obligations outside the claims context, and its interaction with other laws is primarily through evidentiary and procedural dependencies in the claims process.

The compilation provides a limited amendment history. The Statement of Principles concerning cirrhosis of the liver (Reasonable Hypothesis) (No. 1 of 2017) was registered on 4 January 2017 (F2017L00002) and commenced on 23 January 2017 (Endnote 3,Legislation history). The compilation also notes an amendment by the Veterans' Entitlements (Statements of Principles,Cumulative Equivalent Dose) Amendment Determination 2017 (No. 58 of 2017), registered 22 August 2017 (F2017L01067) and commenced 18 September 2017 (Endnote 3).

The primary textual amendment recorded in the endnotes concerns the Schedule 1 definition of “cumulative equivalent dose”, which was revised by the No. 58 of 2017 instrument (Endnote 4,Amendment history: Schedule 1 - Dictionary - "cumulative equivalent dose" rs. No. 58 of 2017). The compiled SOP shows that the cumulative equivalent dose definition now explicitly references the ARPANSA Guide as in force on 2 August 2017 and provides notes explaining scope and methodology (Schedule 1: cumulative equivalent dose). That amendment ties the SOP’s radiation dose assessment method to a dated edition of ARPANSA guidance, and the endnotes identify the registration and commencement dates for that amendment.

The 2017 SOP revoked the prior Statement of Principles concerning cirrhosis of the liver No. 107 of 2007 (s 4). The revocation is a discrete amendment effecting a full replacement of the prior SOP; details of precisely how each factor threshold changed compared to the 2007 SOP are not set out in the text of this SOP but would be available by comparing the two instruments in the legislation register. The compilation notes that it shows the text as amended and in force on 18 September 2017 and that the endnotes include the amendment history.

The instrument contains no later amendment entries in the main text beyond the cumulative equivalent dose amendment recorded as No. 58 of 2017. The compilation warns that uncommenced amendments are not shown and that underlined text in the endnotes indicates provisions not commenced, so practitioners should consult the Legislation Register for any subsequent uncommenced or later amendments affecting this SOP (About this compilation).

Because the Schedule references an external guide “as in force on 2 August 2017”, any subsequent changes in ARPANSA methodology after that date would not automatically alter the SOP unless the SOP is formally amended. The Schedule therefore locks the SOP to that stated edition for the purposes of dose calculation unless another SOP amendment replaces that reference.

Finally, the compilation structure and endnotes provide administrative metadata (registration numbers, commencement dates and amendment identifiers) that practitioners must check for later changes. The endnotes include the standard compendium references (Endnote 1-4) and identify the specific amending instrument (No. 58 of 2017) affecting the cumulative equivalent dose definition.

The text of the instrument contains no references to judicial decisions, tribunal determinations or any litigation history. It does not cite or rely upon any case law, and no examples of judicial interpretation are included. Therefore, within this source there are no recorded cases applying or construing the 2017 SOP.

Practically, because SOPs are determinative in the administrative scheme under the VEA, disputes about the application of this instrument may arise in administrative review or judicial review of claim decisions under the VEA and MRCA. However, the compilation contains no record of such litigation, and it does not identify any legal authorities that have considered or interpreted the content of this SOP. The endnotes and the main text likewise contain no mention of tribunal or court outcomes.

Given that the SOP specifies technical measurement standards (for example, the ARPANSA Guide for cumulative equivalent dose, Schedule 1) and specific clinical thresholds (for chronic infections and for exposure/dose‑based factors), likely sources of litigation, where they occur, would focus on interpretive questions such as:

• the proper application of the ARPANSA dose reconstruction methodology to particular service records when assessing whether the 0.4 sievert threshold is met;

• the interpretation of “clinical onset” and “clinical worsening” in specific medical histories, and how to date those events for the purpose of relating exposure timing to service;

• whether laboratory evidence satisfies the Schedule’s definitions of “chronic infection” (duration and laboratory confirmation);

• the application of section 10(2) to determine when subsections 9(28)-9(55) can be relied upon for material contribution or aggravation, particularly in complex temporal histories where disease arose before, during or after service.

These are logical focal points for contest in claims and reviews, but the instrument itself does not provide a litigation history or illustrative decisions. Practitioners should therefore search tribunal and court databases for subsequent decisions that interpret and apply this SOP in individual cases, because no such material is included in the SOP text or the compilation endnotes.

The instrument contains numerous specific thresholds and definitional details that create practical pitfalls for claimants and advisers. The following items identify concrete “gotchas” grounded in the SOP text.

1. Binary threshold tests, not general causation assertions (s 9). The SOP is constructed as a list of factors which, if established, raise a reasonable hypothesis. Absence of these listed factors does not, within this instrument, create an alternative path to entitlement. Practitioners must therefore avoid relying on general clinical plausibility when none of the listed factors is present.

2. Alcohol thresholds are expressed in kilograms of ethanol over ten year periods (s 9(1)-(2) and Schedule: alcohol). The Schedule defines a standard drink as ten grams of alcohol. Converting the statutory thresholds matters: 110 kilograms of alcohol equals 110,000 grams, which divided by 10 grams per standard drink equals 11,000 standard drinks over ten years, or about 3.01 standard drinks per day averaged over ten years (110 kg / 10 g = 11,000 drinks; 11,000/3650 ≈ 3.01/day). For females, 55 kilograms equals 5,500 standard drinks over ten years, or about 1.51 standard drinks per day on average. Practitioners must ensure consumption histories are converted to these units and supported by record evidence where possible.

3. Timing language,“before the clinical onset” versus “before the clinical worsening” (s 9). The SOP separates factors that apply to initial causation from those that apply to clinical worsening. Advisers must carefully date the clinical onset and any clinically documented worsening. Clinical records must be interrogated to determine which factors apply to each temporal phase.

4. Subsection 10(2) constraint on factors 9(28)-9(55). These factors apply only to material contribution to, or aggravation of, cirrhosis where cirrhosis was suffered or contracted before or during (but did not arise out of) relevant service. This wording creates a narrower scope for these factors: they cannot be used to establish causation where the cirrhosis itself arose out of the service. Establishing the pre‑existing disease and then proving material contribution or aggravation will require historical clinical records.

5. Radiation dose methodology is external and dated (Schedule 1). The cumulative equivalent dose definition explicitly requires calculation “in accordance with the methodology set out in” the ARPANSA guide as in force on 2 August 2017. For radiation claims, dose reconstruction must follow that edition’s methodology. If claimants prefer use of later ARPANSA methodology, the SOP does not permit it unless the SOP itself is amended.

6. Specific drug lists and cumulative doses (s 9(22)-(24), (50)-(51) and Schedule). The SOP names specific drugs (didanosine, stavudine, zalcitabine) in the Schedule and sets concrete cumulative dose or duration thresholds for methotrexate (six months or cumulative 500 mg taken over at least three months). Evidence needs to accurately document duration and cumulative dosing. Generic or related drugs not expressly named will not satisfy the “dideoxynucleoside‑analogue drugs as specified” phrase.

7. Occupational exposure measures and units (s 9(25)-(27), (52)-(54); Schedule: ppm‑years). For vinyl chloride the instrument uses two alternative exposure metrics: a cumulative dose of at least 500 ppm‑years or 1,000 hours of exposure in specific work roles. The Schedule defines ppm‑years as parts per million multiplied by years of exposure. Establishing either requires contemporaneous occupational exposure records or expert reconstruction.

8. Clinical definitions require laboratory confirmation (Schedule 1). Chronic infections (B, C, D, E) all require at least six months duration and laboratory confirmation by serological or nucleic acid markers. Absence of laboratory markers consistent with this standard will be decisive.

9. Death coverage requires contribution by cirrhosis to a terminal event (s 7(5) and Schedule: terminal event). The SOP covers death from a terminal event or condition that was contributed to by cirrhosis. Practitioners must obtain medical cause of death documentation and linkages showing that cirrhosis contributed to the listed terminal events (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function).

10. The SOP revokes its predecessor (s 4). Claims previously assessed under the 2007 SOP should be reviewed for changed thresholds and definitional shifts introduced by the 2017 SOP, especially where radiation dose methodology has been updated.

11. Where a factor is addressed in another SOP, that SOP governs (s 11). This can be a pitfall if practitioners assume the cirrhosis SOP applies to a named disease factor when that disease is the subject of a different SOP. Cross‑checking the other SOP is mandatory.

12. “Inability to obtain appropriate clinical management” is listed as a factor for clinical worsening (s 9(55)). This factor is potentially subjective and will require evidence of attempts to obtain care, barriers encountered, and causal link between absence of management and clinical worsening.

These points are concrete interpretive traps that must be addressed through careful factual and documentary work. Practitioners should therefore translate clinical histories, pharmacological records, occupational exposure logs, laboratory results and service records into the precise units and timeframes the SOP requires.

Compliance in this context means assembling evidence and framing factual submissions so that the particular factor(s) in section 9 are established and related to relevant service as required by section 10. The SOP prescribes the material elements; practitioners should structure evidence-gathering and submissions to match those elements.

1. Establish the diagnosis and date clinical onset/worsening (s 7(2), s 9): Obtain contemporaneous clinical records documenting the diagnosis of cirrhosis and the dates of first clinical signs, and any subsequent clinically documented worsening. Where pathology or imaging reports exist, include them to demonstrate the presence of severe fibrosis and regenerative nodules consistent with the SOP definition. For death claims, procure the cause of death certificate and hospital records showing contribution of cirrhosis to the terminal event (s 7(5), Schedule: terminal event).

2. Map factors in s 9 to documentary evidence:

• Alcohol: Convert consumption histories to mass of ethanol using the Schedule definition of 10 grams per standard drink. Explicitly calculate total kilograms consumed within any ten year period before onset/worsening and show the arithmetic (for example, 11,000 standard drinks = 110 kg ethanol). Use contemporaneous notes, general practitioner records, hospital notes and any dependency treatment records to evidence consumption.

• Ionising radiation: Commission or obtain dose reconstructions calculated in accordance with the ARPANSA Guide as in force on 2 August 2017 (Schedule 1). Ensure reconstructed cumulative equivalent dose to the liver is calculated and documented. Include all relevant external and internal exposure sources, and exclude normal background radiation in accordance with the Schedule.

• Chronic infections (hepatitis B, C, D, E): Provide laboratory evidence showing serological or nucleic acid markers and documentation that the infection persisted for at least six months prior to clinical onset/worsening (Schedule 1). Time‑stamp laboratory results and include clinical notes referencing chronic infection.

• Drug exposures: For methotrexate, provide prescribing records showing duration (at least six months) or cumulative dose (at least 500 mg over at least a three month period). For dideoxynucleoside agents, provide prescription and dispensing records for didanosine, stavudine or zalcitabine demonstrating at least six months of treatment prior to onset/worsening.

• Occupational/chemical exposures: For vinyl chloride and carbon tetrachloride, obtain employer records, safety logs, material safety data sheets and contemporaneous exposure monitoring. Translate exposure into the units required (ppm‑years, hours of exposure) and obtain expert occupational hygiene reports if direct records are inadequate.

• Metabolic/genetic conditions: Obtain laboratory tests for ferritin and transferrin saturation to evidence iron overload; genetic test results or specialist reports for Wilson's disease, Gaucher's disease and alpha‑1 antitrypsin deficiency.

• Clinical syndromes: For Budd‑Chiari, veno‑occlusive disease and severe right‑sided cardiac failure, obtain specialist cardiology and hepatology reports and imaging/pathology demonstrating the condition and duration criteria (for example continuous period of at least six months for Budd‑Chiari and severe right‑sided cardiac failure as required in s 9(21), s 9(14) and s 9(41)).

3. Demonstrate relation to relevant service (s 10(1) and Schedule: relevant service): Provide service records showing the timing and nature of relevant service (operational, peacekeeping, hazardous, nuclear test defence, warlike, non‑warlike). Match exposure or disease timing to the period of service to show the required relationship. For subsections 9(28)-9(55), also demonstrate that cirrhosis was suffered or contracted before or during service (but did not arise out of service) if the claimant is relying on those factors (s 10(2)).

4. Cross‑check other SOPs (s 11): If a factor refers to a disease or injury covered by another SOP, obtain and apply the terms of that SOP. For example, if a factor references chronic hepatitis that is covered in another SOP, ensure the claim is presented under that SOP’s terms as required by s 11.

5. Use appropriate technical reports: Where the SOP requires technical measurement or reconstruction (radiation, occupational exposure), commission expert reports that expressly adopt the methods referenced in the SOP (for radiation, use the ARPANSA Guide edition specified). Ensure experts explicitly address the SOP thresholds and translate their findings into the instrument’s language (for example, state the cumulative equivalent dose to the liver in sieverts).

6. Address gaps proactively: For factors dependent on continuous periods (for example six months of cardiac failure or veno‑occlusive disease), assemble longitudinal clinical documentation showing continuity. For inability to obtain appropriate clinical management (s 9(55)), document attempts to obtain care, refusals or lack of access, and medical consequences.

7. Prepare clear calculations and conversions: Because several thresholds use non‑intuitive units (kilograms of alcohol, ppm‑years, sieverts, cumulative drug doses in milligrams), prepare annexes with arithmetic showing the conversion from clinical/occupational records to the statutory units.

8. Anticipate and meet laboratory standards: For chronic infection claims, ensure laboratory test reports include the specific serological or nucleic acid markers referenced by the Schedule, and that testing dates show at least six months duration prior to onset/worsening.

9. Maintain service/exposure chronology: Build a timeline linking service episodes, exposures, treatment dates, laboratory tests, onset of symptoms and any episodes of clinical deterioration. The SOP’s temporal requirements make chronology essential.

10. When in doubt, seek specialist opinions tied to SOP language: Requests for clinical opinions should ask treating specialists to comment directly on whether the specific SOP thresholds are met and whether the factor in question can reasonably be said to be related to relevant service, addressing the SOP wording and definitions.

Following the instrument closely when compiling evidence is the practical compliance path. The SOP supplies precise thresholds and definitional rules; compliance therefore requires translating medical, pharmacological and exposure histories into those precise terms and documenting the relation to relevant service per section 10 and Schedule 1.